Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG

Henrı́quez, I.; Rodrı́guez-Antolı́n, A.; Cassinello, Javier; Segundo, Carmen González San; Unda, Miguel; Gallardo, Enrique; López-Torrecilla, J.; Juárez, Álvaro; Arranz, José Ángel

doi:10.1007/s12094-017-1726-y

Cited by 3 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For all the fitness functions above, chemotherapy is implemented by the introduction of a cost s, which corresponds to the strength of the chemotherapy regiment. Chemotherapy is widely used in treating hormone-sensitive and -insensitive metastatic prostate cancer [27]. As chemotherapy options like docetaxel become more widely used, so does the importance of understanding how to better administer them in order to minimize the possibility that resistant phenotypes emerge.…”

Section: Chemotherapymentioning

confidence: 99%

Fractionated Follow-Up Chemotherapy Delays the Onset of Resistance in Bone Metastatic Prostate Cancer

Warman

Kaznatcheev

Araujo

et al. 2018

Games

View full text Add to dashboard Cite

Prostate cancer to bone metastases are almost always lethal. This results from the ability of metastatic prostate cancer cells to co-opt bone remodeling, leading to what is known as the vicious cycle. Understanding how tumor cells can disrupt bone homeostasis through their interactions with the stroma and how metastatic tumors respond to treatment is key to the development of new treatments for what remains an incurable disease. Here we describe an evolutionary game theoretical model of both the homeostatic bone remodeling and its co-option by prostate cancer metastases. This model extends past the evolutionary aspects typically considered in game theoretical models by also including ecological factors such as the physical microenvironment of the bone. Our model recapitulates the current paradigm of the "vicious cycle" driving tumor growth and sheds light on the interactions of heterogeneous tumor cells with the bone microenvironment and treatment response. Our results show that resistant populations naturally become dominant in the metastases under conventional cytotoxic treatment and that novel schedules could be used to better control the tumor and the associated bone disease compared to the current standard of care. Specifically, we introduce fractionated follow up therapy-chemotherapy where dosage is administered initially in one solid block followed by alternating smaller doses and holidays-and argue that it is better than either a continuous application or a periodic one. Furthermore, we also show that different regimens of chemotherapy can lead to different amounts of pathological bone that are known to correlate with poor quality of life for bone metastatic prostate cancer patients.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Fractionated Follow-Up Chemotherapy Delays the Onset of Resistance in Bone Metastatic Prostate Cancer

Warman

Kaznatcheev

Araujo

et al. 2018

Games

View full text Add to dashboard Cite

show abstract

“…For all the fitness functions above, chemotherapy is implemented by the introduction of a cost s, which corresponds to the the strength of the chemotherapy regiment. Chemotherapy is widely used in treating hormonesensitive and insensitive metastatic prostate cancer [24]. As chemotherapy options like docetaxel become more widely used, so does the importance of understanding how to better administer them so as to minimize the possibility that resistant phenotypes emerge.…”

Section: Modelmentioning

confidence: 99%

Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer

Warman

Kaznatcheev

Araujo

et al. 2018

Preprint

View full text Add to dashboard Cite

Prostate cancer to bone metastases are almost always lethal. This results from the ability of metastatic prostate cancer cells to co-opt bone remodeling leading to what is known as the vicious cycle. Understanding how tumor cells can disrupt bone homeostasis through their interactions with the stroma and how metastatic tumors respond to treatment is key to the development of new treatments for what remains an incurable disease. Here we describe an evolutionary game theoretical model of both the homeostatic bone remodeling and its co-option by prostate cancer metastases. This model extends past the evolutionary aspects typically considered in game theoretical models by also including ecological factors such as the physical microenvironment of the bone. Our model recapitulates the current paradigm of the "vicious cycle" driving tumor growth and sheds light on the interactions of heterogeneous tumor cells with the bone microenvironment and treatment response. Our results show that resistant populations naturally become dominant in the metastases under conventional cytotoxic treatment and that novel schedules could be used to better control the tumor and the associated bone disease compared to the current standard of care. Specifically, we introduce fractionated follow up therapy -chemotherapy where dosage is administered initially in one solid block followed by alternating smaller doeses and holidays -and argue that it is better than either a continuous application or a periodic one. Furthermore, we also show that different regimens of chemotherapy can lead to different amounts of pathological bone that are known to correlate with poor quality of life for bone metastatic prostate cancer patients.keywords: evolutionary game theory -prostate cancer bone metastasis -chemotherapy -heterogeneity -resistance

show abstract

“…Para el resto de los grupos, donde sí se aconseja el estudio por imagen para una correcta estadificación, el grupo español de las tres sociedades de Uro-Oncología (URONCOR, GUO and SOGUG) recomienda, en el consenso que crearon en 2017, la realización de RMmp que ha demostrado un 77-80% de eficacia en la detección de afectación extracapsular (112), superior al tacto rectal y a otras técnicas de imagen para estadificación local. Según este consenso (con un nivel de evidencia 2b, nivel de recomendación A) se debe realizar RMmp y GGO para una correcta estadificación local, regional y a distancia (113).…”

Section: Estadificación Y Grupos De Riesgounclassified

“…El mismo grupo reserva la utilización de la tomografía por emisión de positrones con colina (PET/TAC colina) para la detección de afectación ganglionar o a distancia para pacientes con pruebas convencionales negativas, pero con alta sospecha de afectación clínica (113).…”

Section: Estadificación Y Grupos De Riesgounclassified

“…• La prostatectomía radical con linfadenectomía de ganglios linfáticos pélvicos extendida también puede ser una opción para pacientes de muy alto riesgo. Estos pacientes deberían estar muy seleccionados, según recomiendan el consenso del grupo español de Uro-Oncología (113) aunque no debería ser la opción elegida para estos pacientes si tenemos en cuenta el análisis retrospectivo con el mayor número de pacientes estudiado hasta la fecha (1809 pacientes) que encontró que las tasas de mortalidad cáncer específicas a cinco años fueron más bajas en aquellos tratados con radioterapia externa y braquiterapia intersticial en comparación con radioterapia externa exclusiva o prostatectomía radical (128).…”

Section: Tratamiento Según Grupos De Riesgounclassified

See 1 more Smart Citation

Enzalutamida como radiopotenciador de líneas celulares de cáncer de próstata

Aguirre¹

View full text Add to dashboard Cite

En este trabajo evaluamos el papel de enzalutamida como potenciador de la radioterapia en líneas celulares de cáncer de próstata, sirviendo como experimento de apoyo de investigación básica para investigación clínica. En este proyecto, proponemos estudiar este tratamiento combinado en dos líneas celulares humanas de cáncer de próstata representativas, LNCaP y PC3. Los objetivos concretos son los siguientes: analizar el efecto del tratamiento con enzalutamida antes de la radioterapia sobre la proliferación de células tumorales prostáticas evaluando si existe un efecto sinérgico entre ambas; comprobar el grado de apoptosis conseguido tras la combinación del tratamiento; y abordar el potencial de la tecnología de monitorización en tiempo real (RTCA) para probar si el régimen terapéutico combinatorio de radioterapia con enzalutamida en las líneas celulares de cáncer de próstata puede justificar su aplicación de esta combinación en pacientes con cáncer de próstata localizado.

show abstract

Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG

Abstract: This article reviews important issues concerning high-risk PCa. URONCOR, GUO, and SOGUG on behalf of the Spanish Groups of Uro-Oncology Societies have reached a consensus addressing a practical recommendation on definition, diagnosis, and management of high-risk PCa.

Cited by 3 publications

References 48 publications

Fractionated Follow-Up Chemotherapy Delays the Onset of Resistance in Bone Metastatic Prostate Cancer

Fractionated Follow-Up Chemotherapy Delays the Onset of Resistance in Bone Metastatic Prostate Cancer

Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer

Enzalutamida como radiopotenciador de líneas celulares de cáncer de próstata

Contact Info

Product

Resources

About